RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Ultragenyx Pharmaceutical Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$15.07+0.53 (+3.65%)
Close on Oct 19, 2026
- Market cap
- $1.54B
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Ultragenyx Pharmaceutical has not reported a dividend
No dividend per share appears in Ultragenyx Pharmaceutical's annual filings since fiscal 2011.